Silexion Therapeutics (NASDAQ:SLXN) Shares Down 1.1% – Time to Sell?

Shares of Silexion Therapeutics Corp (NASDAQ:SLXN) dropped 1.1% during mid-day trading on Friday . The company traded as low as $1.68 and last traded at $1.72. Approximately 2,679 shares changed hands during mid-day trading, a decline of 92% from the average daily volume of 31,712 shares. The stock had previously closed at $1.74.

Wall Street Analyst Weigh In

Several analysts have weighed in on the company. Litchfield Hills Research initiated coverage on Silexion Therapeutics in a research report on Monday, December 15th. They set a “buy” rating on the stock. Wall Street Zen cut Silexion Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, December 20th. Finally, Zacks Research raised Silexion Therapeutics to a “hold” rating in a research note on Tuesday, December 16th. Two equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $75.00.

Silexion Therapeutics Stock Performance

The company has a debt-to-equity ratio of 0.22, a quick ratio of 3.97 and a current ratio of 3.97. The stock has a market capitalization of $5.38 million, a P/E ratio of -0.15 and a beta of -0.03. The business has a 50-day moving average price of $1.93 and a 200 day moving average price of $3.35.

About Silexion Therapeutics

Silexion Therapeutics LTD, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, which is in pre-clinical studies for the treatment of prostate cancer; and GBM-LODER that is in pre-clinical studies to target Glioblastoma Multiform, a malignant primary brain tumor.